Showcasing Clinical Findings for Toferson: Disease-Modifying Capabilities Targeting SOD1 Genetic Mutation

Time: 2:15 pm
day: Day Two AM


  • Explaining ongoing clinical strategy in extended phase 3 clinical trials
  • Outlining lessons learnt regarding clinical endpoints from interactions with regulatory authorities
  • What is the future for therapies targeting familial ALS seeking approval?